Tang, Shou-Hung <br/><br/>
Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo.  [electronic resource] 

 -  Oncotarget  Nov 2014 
 - 10342-55 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.1867  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Apoptosis--drug effects<br/>Carcinoma--drug therapy<br/>Cell Growth Processes--drug effects<br/>Cell Line, Tumor<br/>Down-Regulation<br/>Drug Resistance--drug effects<br/>Emodin--administration & dosage<br/>Enhancer of Zeste Homolog 2 Protein<br/>G2 Phase Cell Cycle Checkpoints--drug effects<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>In Vitro Techniques<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Neoadjuvant Therapy<br/>Neoplasm Staging<br/>Polycomb Repressive Complex 2--antagonists & inhibitors<br/>Proteasome Endopeptidase Complex--metabolism<br/>Urinary Bladder Neoplasms--drug therapy<br/>Xenograft Model Antitumor Assays